positive
AI-driven drug discovery startup secures US$120 million to accelerate clinical pipelines
An AI-enabled drug discovery startup has raised US$120 million in a new funding round aimed at accelerating pre-clinical and clinical development of small-molecule therapies. The company uses generative AI models to identify high-potential compounds, simulate molecular interactions, and shorten traditional R&D cycles. Investors noted rising interest in platforms that integrate biological datasets, proprietary algorithms, and automated lab workflows to reduce discovery timelines. The funding will support partnerships with pharmaceutical companies, expansion of autonomous wet labs, and regulatory preparation for early-phase trials.
Analysts say AI is becoming a central driver of drug-development competitiveness.
Reuters• By Pooja Kumari
Explore:Mutual Fund Themes
positive
AI-driven drug discovery startup secures US$120 million to accelerate clinical pipelines
An AI-enabled drug discovery startup has raised US$120 million in a new funding round aimed at accelerating pre-clinical and clinical development of small-molecule therapies. The company uses generative AI models to identify high-potential compounds, simulate molecular interactions, and shorten traditional R&D cycles. Investors noted rising interest in platforms that integrate biological datasets, proprietary algorithms, and automated lab workflows to reduce discovery timelines. The funding will support partnerships with pharmaceutical companies, expansion of autonomous wet labs, and regulatory preparation for early-phase trials.
Analysts say AI is becoming a central driver of drug-development competitiveness.
Reuters• By Pooja Kumari
Explore:Mutual Fund Themes
Breaking
positive
AI-driven drug discovery startup secures US$120 million to accelerate clinical pipelines
1 min read
91 words
An AI drug discovery startup raised US$120 million to speed up molecular development and expand automated lab and clinical pipelines.
An AI-enabled drug discovery startup has raised US$120 million in a new funding round aimed at accelerating pre-clinical and clinical development of small-molecule therapies. The company uses generative AI models to identify high-potential compounds, simulate molecular interactions, and shorten traditional R&D cycles. Investors noted rising interest in platforms that integrate biological datasets, proprietary algorithms, and automated lab workflows to reduce discovery timelines. The funding will support partnerships with pharmaceutical companies, expansion of autonomous wet labs, and regulatory preparation for early-phase trials.
Analysts say AI is becoming a central driver of drug-development competitiveness.
An AI-enabled drug discovery startup has raised US$120 million in a new funding round aimed at accelerating pre-clinical and clinical development of small-molecule therapies. The company uses generative AI models to identify high-potential compounds, simulate molecular interactions, and shorten traditional R&D cycles. Investors noted rising interest in platforms that integrate biological datasets, proprietary algorithms, and automated lab workflows to reduce discovery timelines. The funding will support partnerships with pharmaceutical companies, expansion of autonomous wet labs, and regulatory preparation for early-phase trials.
Analysts say AI is becoming a central driver of drug-development competitiveness.
Tags:
startups
AI
startups
AI
drug discovery
pharma
funding